Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia

Department of Medicine, Department of Veterans Affairs Medical Center, Fresno, California.

The anti-ischemic effects of atenolol and nifedipine were compared in a randomized double-blind crossover manner in 24 patients with stable exertional angina and transient silent ischemia during ambulatory electrocardiographic (ECG) monitoring. Both atenolol and nifedipine were effective (p less than 0.005) in reducing the average number and duration of transient ischemic events, but therapy with atenolol was associated with a significantly greater reduction in the mean number (p less than 0.05) and duration (p less than 0.01) of silent ischemic events. Analyses of the silent ischemic activity during the morning hours revealed that only therapy with atenolol produced a significant reduction in the average duration per patient (139 +/- 54 vs. 1,609 +/- 468 s, p less than 0.01) and in the average duration of silent ischemia per event between 6 AM and 12 noon (62 +/- 21 vs. 208 +/- 24 s, p less than 0.005). There were fewer adverse experiences during therapy with atenolol. These results show that although both atenolol and nifedipine are effective in reducing silent ischemic events, treatment with atenolol is associated with significantly greater efficacy, particularly on the morning surge of silent myocardial ischemia.

This article has been cited by other articles:

				F. Enseleit and F. Duru Long-term continuous external electrocardiographic recording: a review. Europace, April 1, 2006; 8(4): 255 - 266. [Abstract] [Full Text] [PDF]

				V. Snow, P. Barry, S. D. Fihn, R. J. Gibbons, D. K. Owens, S. V. Williams, C. Mottur-Pilson, K. B. Weiss, and for the American College of Physicians/American Co Primary Care Management of Chronic Stable Angina and Asymptomatic Suspected or Known Coronary Artery Disease: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, October 5, 2004; 141(7): 562 - 567. [Abstract] [Full Text] [PDF]

				M. H. Crawford, S. J. Bernstein, P. C. Deedwania, J. P. DiMarco, K. J. Ferrick, A. Garson Jr, L. A. Green, H. L. Greene, M. J. Silka, P. H. Stone, et al. ACC/AHA guidelines for ambulatory electrocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography) developed in collaboration with the North American Society for Pacing and Electrophysiology J. Am. Coll. Cardiol., September 1, 1999; 34(3): 912 - 948. [Full Text] [PDF]

				W. B. Stason, C. H. Schmid, D. Niedzwiecki, G. W. Whiting, J.-F. Caubet, D. Cory, D. Luo, S. D. Ross, and T. C. Chalmers Safety of Nifedipine in Angina Pectoris : A Meta-Analysis Hypertension, January 1, 1999; 33(1): 24 - 31. [Abstract] [Full Text] [PDF]

				S. Goldstein {beta}-Blockers in Hypertensive and Coronary Heart Disease Arch Intern Med, June 24, 1996; 156(12): 1267 - 1276. [Abstract] [PDF]

				H. Purcell Dr. and D. Mulcahy Circadian Rhythms and the Onset of Myocardial Infarction: Clinical Implications European Journal of Cardiovascular Prevention & Rehabilitation, December 1, 1995; 2(6): 510 - 514. [Abstract] [PDF]

				ATENOLOL VS. NIFEDIPINE FOR SILENT ISCHEMIA Journal Watch (General), March 26, 1991; 1991(326): 5 - 5. [Full Text]